Editors:
- Represents the first text of its kind, designed to give the reader a complete overview of prodrugs: the current status of the prodrug concept and its many applications and successes in overcoming formulation and delivery of problematic drugs
- Replete with examples of approved and marketed prodrugs, including 25 case studies of marketed prodrugs from which one might learn and apply to future strategic endeavors in the development of prodrug candidates
- Introduces the topic to the novice as well as professional in the design of prodrugs
Part of the book series: Biotechnology: Pharmaceutical Aspects (PHARMASP, volume V)
Buy it now
Buying options
Tax calculation will be finalised at checkout
Other ways to access
This is a preview of subscription content, log in via an institution to check for access.
Table of contents (57 chapters)
-
Front Matter
-
A Case for Prodrugs
-
Front Matter
-
-
Problems Addressable by Prodrugs
-
Front Matter
-
About this book
Prodrugs are substances administered in an inactive form that is then metabolized in the body in vivo into the active compound. The rationale behind administering prodrugs is to optimize absorption, distribution, metabolism, and excretion of these drugs. Since first described in the 1950s, prodrugs continue to be a fertile area of research. There are a number of small pharmaceutical/biotech companies dedicated to using prodrugs for the delivery of older but problematic drugs as well as to developing broad-based prodrug technologies for application to new and future drugs. These volumes represent a comprehensive guide to prodrugs and will guide the reader through the current status of the prodrug concept and its many applications and to highlight its many successes in overcoming formulation and delivery of problematic drugs.
Reviews
From the reviews:
"The editors provide a comprehensive overview on early and current prodrug strategies. … medicinal chemists will highly appreciate this book. … the book should be available in the libraries of every pharmaceutical and small-molecule biotech company." (Hugo Kubinyi, ChemMedChem, Issue 3, 2008)
Editors and Affiliations
-
University of Kansas, Lawrence, USA
Valentino J. Stella, Ronald T. Borchardt
-
Bristol-Myers Squibb Company, Princeton, USA
Michael J. Hageman
-
Gilead Sciences, Foster City, USA
Reza Oliyai
-
Roche Palo Alto, LLC, Palo Alto, USA
Hans Maag
-
Hoffmann-La Roche, Inc., Nutley, USA
Jefferson W. Tilley
Bibliographic Information
Book Title: Prodrugs
Book Subtitle: Challenges and Rewards
Editors: Valentino J. Stella, Ronald T. Borchardt, Michael J. Hageman, Reza Oliyai, Hans Maag, Jefferson W. Tilley
Series Title: Biotechnology: Pharmaceutical Aspects
DOI: https://doi.org/10.1007/978-0-387-49785-3
Publisher: Springer New York, NY
eBook Packages: Biomedical and Life Sciences, Biomedical and Life Sciences (R0)
Copyright Information: Springer-Verlag New York 2007
Hardcover ISBN: 978-0-387-49782-2Published: 12 March 2007
Softcover ISBN: 978-1-4939-5050-8Published: 04 May 2017
eBook ISBN: 978-0-387-49785-3Published: 26 August 2007
Edition Number: 1
Number of Pages: XVIII, 1464
Topics: Pharmacology/Toxicology
